Health Care Reform and the Changing Dynamics Between Payers and Drug Makers
This article was originally published in RPM Report
Why drug makers should pay close attention to the pressures bearing down on payers.
You may also be interested in...
When you think about the impact of the Food & Drug Administration’s focus on real-world drug safety, the disruptive implications of the Affordable Care Act, and the relentless pressure to find savings in health care, it is easy to see the dangers posed to biopharma companies. But those forces aren’t all negative. In fact, they are helping to mobilize government, consumer groups and payors to push hard on at least one decidedly pro-pharma agenda: improving adherence with prescription medicines.
The health care reform debate was wild and wooly-but it is hard to imagine a better outcome for the biopharma sector in general and the Pharmaceutical Research & Manufacturers of America in particular. So why isn't anybody celebrating?
Since the end of World War II, the employer-based health plan has been part of the social compact for many Americans. While Senator Barack Obama’s proposal for expanded coverage is greeted enthusiastically by those who favor change, Senator John McCain’s proposal offers the boldest departure from business as usual.